case / 13 Aug 2020
Setterwalls assisted Isofol when entering into a licensing agreement with Solasia
Isofol Medical enters licensing agreement with Solasia Pharma to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in in Japan.
Setterwalls adviced Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market) when entering into a license agreement with Solasia Pharma K.K, a specialized oncology company headquartered in Japan. Under the terms of the agreement, Isofol will receive a total amount of ~$ 100 million* (SEK 890 million*) as upfront, development, regulatory and sales-based milestone payments and clinical development cost. In addition, Isofol will receive tiered royalties on net sales in solid double digit figures. The license agreement is initially focuses on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin. Additional indications will be evaluated jointly by Solasia and Isofol. Isofol retains rights to arfolitixorin in the rest of the world.